Clinical trials: Blind
Fungal Infection
Safety and Pharmacokinetics of Rezafungin
This is a Phase 1, double-blind, placebo-controlled trial in three parts. A single ascending dose (SAD) study in six cohorts receiving a single subcutaneous (SC) dose of 1, 10, 30, 60, 100, or 200 mg of rezafungin; a multiple…
- Trial name
- NCT04117607
- Testing
- Rezafungin
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Rheumatoid Arthritis
Safety, Tolerability and Efficacy of MBS2320 in Patients With Rheumatoid Arthritis
Rheumatoid arthritis (RA) affects 1 percent of the population worldwide and up to 40 percent of patients don't respond to current treatments.
- Trial name
- NCT03139136
- Testing
- MBS2320
- Where
- 3 sites in Georgia, Moldova and 1 more
- Volunteers
- 121 people
- Sponsor
- Modern Biosciences Ltd
Cough
The Safety, Tolerability, PK and PD of GSK2339345 in Healthy Subjects
This is a First Time in Human (FTIH) study for the sodium channel inhibitor, GSK2339345. The study is split into two parts. Part A will assess the safety and tolerability of the new drug.
- Trial name
- FTIH (NCT01494636)
- Testing
- GSK2339345 (solution), GSK2339345 (nebulised), Lidocaine
- Where
- United Kingdom
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Neuromodulation, Upper Limb
Analysis of Neuromodulation as a Complementary Treatment to Evidence-based Clinical Intervention in Subjects With Musculoskeletal Pathology of the Upper Limb: a Double-blind Randomized Clinical Trial
This project aims to analyze the use of neuromodulation within a treatment protocol for musculoskeletal conditions of the upper limb, as well as to determine the difference between two and three sessions per week.
- Conditions
- Neuromodulation, Upper Limb, Musculoskeletal Disorders
- Trial name
- NCT07165392
- Testing
- Neuromodulation, Physical Exercise, Stretching
- Volunteers
- 120 people
- Sponsor
- University of Malaga
Type 2 Diabetes Mellitus, Diabetes
Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of REMD-477 in Subjects With Type 2 Diabetes Mellitus
This is a randomized, placebo-controlled, double-blind, dose escalation study to evaluate safety, tolerability, PK and PD of single and repeated SC doses of REMD-477 in Type 2 diabetic subjects.
- Trial name
- NCT02455011
- Testing
- REMD-477
- Where
- 3 sites in United States
- Volunteers
- 75 people
- Sponsor
- REMD Biotherapeutics, Inc.
COVID-19
INB03 for the Treatment of Pulmonary Complications From COVID-19
The purpose of this study is to determine whether XPro1595 can prevent the progression of respiratory complications in COVID19 patients.
- Trial name
- NCT04370236
- Testing
- INB03
- Where
- 9 sites in United States
- Volunteers
- 79 people
- Sponsor
- Inmune Bio, Inc.
Pruritus
Study of Itch Control by VLY-686 in Healthy Volunteers After Intradermal Injections of Substance P
The purpose of this study is to test whether VLY-686 can prevent or reduce the itch and dermatological reaction observed after healthy volunteers are injected with Substance P in comparison with placebo.
- Trial name
- NCT01919944
- Testing
- VLY-686
- Where
- Switzerland
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Vanda Pharmaceuticals
HIV Infections
A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of rgp120/HIV-1MN (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults.
PRIMARY: To examine the safety and potential improvement in immune responses elicited by combining rsgp120/HIV-1MN with the adjuvant QS-21.
- Trial name
- NCT00001044
- Testing
- Aluminum hydroxide, QS-21, rgp120/HIV-1MN
- Where
- 4 sites in United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Parkinson's Disease
A Phase 2b Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa
The purpose of this study is to establish the efficacy of 20 mg/day and 40 mg/day doses of istradefylline for reducing the mean total hours of awake time per day spent in the OFF state in patients with advanced Parkinson's…
- Trial name
- NCT00455507
- Testing
- Istradefylline
- Where
- Japan
- Volunteers
- 363 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Postoperative Residual Curarization, Neuromuscular Block
Reversal With Low Doses of Sugammadex in Patients Undergoing Non-cardiac Surgery
Neuromuscular blocking agents (NMBA) are among the most commonly used drugs during general anesthesia and may induce complete muscle paralysis.They are used clinically to facilitate endotracheal intubation and to optimize…
- Trial name
- NCT03460509
- Testing
- Sugammadex
- Volunteers
- 144 people
- Sponsor
- The Hospital of Vestfold
Clostridium Infections
Safety and Immunogenicity Study of GSK's Clostridium Difficile Vaccine 2904545A When Administered in Healthy Adults Aged 18-45 Years and 50-70 Years
The purpose of this study is to generate safety, reactogenicity (assessment of any expected or unexpected side effect of the vaccine) and immunogenicity (ability to induce an immune response) data for the development of a…
- Trial name
- NCT04026009
- Testing
- C. difficile investigational vaccine based on the F2 antigen (GSK2904545A), C. difficile investigational vaccine based on the F2 antigen (GSK2904545A) adjuvanted with AS01B
- Where
- Belgium
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Acne Vulgaris, Acne
Study of NVN1000 Topical Gel and Topical Gel Vehicle in the Treatment of Moderate to Severe Acne Vulgaris
The primary objective of this study is to compare the tolerability, safety and efficacy of NVN1000 Topical Gel and Topical Gel Vehicle in the treatment of subjects with moderate to severe acne vulgaris.
- Trial name
- NCT01556698
- Testing
- NVN1000, Vehicle
- Where
- Dominican Republic
- Volunteers
- 70 people
- Sponsor
- Novan, Inc.
Renal Transplant Donor of Left Kidney, Renal Transplant Donor of Right Kidney
Lowering Uric Acid in Live Kidney Donors
Recently there was described an increase in left ventricular mass after kidney donation. It is uncertain whether this is reversible or not.
- Trial name
- AL-DON (NCT03353298)
- Testing
- Allopurinol 300 mg
- Where
- Norway
- Volunteers
- 71 people
- Sponsor
- Oslo University Hospital
Tuberculosis, HIV Infections
Safety and Immunogenicity of AERAS-402 in HIV-infected, Bacillus Calmette-Guerin (BCG)-Vaccinated Adults
This was a Phase II, randomized, double-blind, placebo-controlled trial conducted at 1 site in South Africa. A total of 26 subjects were randomized 1:1 to receive 2 doses of either AERAS-402 at 3 x 10^10 vp (N=13) or placebo…
- Trial name
- NCT01017536
- Testing
- AERAS-402
- Where
- South Africa
- Volunteers
- 26 people
- Sponsor
- Aeras
Stress Urinary Incontinence
Evaluation Of The Ability Of Fesoterodine To Increase Urethral Pressure In Stress Urinary Incontinence Patients
The hypothesis under evaluation is that fesotorodine may provide clinical benefit in the treatment of the condition of stress urinary incontinence
- Trial name
- NCT01042236
- Testing
- Fesoterodine
- Where
- Denmark
- Volunteers
- 22 people
- Sponsor
- Pfizer
Diabetes Mellitus, Type 2
A Phase 2 Study of Cyclo-Z in Subjects With Type 2 Diabetes
This is a double-blind, randomized, placebo-controlled, parallel-group comparison study to evaluate the efficacy and safety of Cyclo-Z vs. placebo in adult subjects with type 2 diabetes.
- Trial name
- NCT03560271
- Testing
- Cyclo-Z
- Where
- 20 sites in United States
- Volunteers
- 256 people
- Sponsor
- NovMetaPharma Co., Ltd.
Atopic Dermatitis
A Single-ascending Dose (Part A) and Repeat-dose (Part B) Study to Investigate the Safety, Pharmacokinetics and Efficacy (Part B Only) of UCB1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B)
The purpose of the study is to investigate the safety and tolerability of single-ascending doses of UCB1381 (intravenous and subcutaneous) in healthy study participants and after repeat intravenous dosing in study participants…
- Trial name
- NCT05277571
- Testing
- UCB1381
- Where
- 16 sites in United States
- Volunteers
- 109 people, healthy volunteers welcome
- Sponsor
- UCB Biopharma SRL
Healthy Volunteers
A Single Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of RBD1016
This is a single dose-escalation phase Ⅰa clinical study to observe the safety and pharmacokinetic profiles of RBD1016 in healthy subjects.
- Trial name
- NCT04685564
- Testing
- RBD1016
- Where
- Australia
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Suzhou Ribo Life Science Co. Ltd.
Influenza, H7N9 Influenza
Safety and Immunogencity of H7N9 Influenza Antigen With 2 Adjuvant Formulations in Healthy Adults in Brazil
The overall aim of this study is to evaluate the safety, immunogenicity and dose sparing effects of H7N9 influenza antigen formulated with 2 different adjuvants .
- Trial name
- NCT03330899
- Testing
- H7N9 antigen + adjuvant IB160, H7N9 antigen + adjuvant SE, H7N9 antigen without adjuvant
- Where
- 3 sites in Brazil
- Volunteers
- 432 people, healthy volunteers welcome
- Sponsor
- Butantan Institute
Microbiome of the Axillae
Effects of a Zinc Oxide Underarm Formula on Normal and Injured Skin in Healthy Volunteers
Bothersome odor from the axilla is in most cases caused by Corynebacterium spp. Anti-microbial effects of zinc oxide (ZnO) are well documented.
- Trial name
- ZINC-ON (NCT03221699)
- Testing
- Formula with ZnO, Formula without ZnO
- Where
- Denmark
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Lars Nannestad Jorgensen